The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISTH 2024 | An overview of platelet dysfunction in patients with myeloproliferative neoplasms
Chloe James, MD, PhD, University Hospital of Bordeaux, Bordeaux, France, summarizes recent advancements in the understanding of platelet dysfunction in myeloproliferative neoplasms (MPNs). Thrombotic events occur more frequently in patients with MPNs than healthy controls, and studies have shown that this could be due to platelet hyperactivation. Additionally, other studies demonstrated that JAK2-mutated platelets can activate neutrophils, which form neutrophil extracellular traps (NETs) and can promote thrombosis. Administration of aspirin, an antiplatelet agent, is therefore beneficial in reducing thrombosis for patients with MPNs by reducing both platelet and neutrophil activation. This interview took place at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
